EBS
Emergent BioSolutions Inc.
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · US
$6.38
+2.41%Price chart
Aug 13Aug 18Aug 21Aug 26Aug 31Sep 3Sep 9Sep 14
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−32.5x
Market Cap
$327.12M
MomentumView details →
1D Return
+2.41%
YTD Return
−47.86%
RSI (14)
57.7
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−32.5x
Market Cap
$327.12M
RSI (14)
57.7
MomentumView details →
1D Return
+2.41%
YTD Return
−47.86%
SummaryUpdated Jun 1, 2026
Emergent BioSolutions Inc. (NYSE:EBS) is a specialized life sciences company founded in 1998 and headquartered in Gaithersburg, Maryland. The company went public in 2006 and has evolved into a leading provider of medical countermeasures and emergency response solutions for public health threats. Emergent focuses on addressing chemical, biological, radiological, nuclear, and explosive threats, as well as emerging infectious diseases and opioid overdose emergencies. The company has undergone significant strategic transformation in recent years, streamlining operations and focusing on its core competencies in biodefense and overdose prevention.
Similar companies
Latest newsMore news →
Emergent BioSolutions Inc. completed the repurchase of $75 million aggregate principal amount of its 3.875% Senior Unsecured Notes due 2028, spending about $68 million in cash at an average price of 90.6% of face value, reducing the outstanding balance to approximately $364.7 million.12d agoEmergent BioSolutions received a contract modification valued at approximately $24 million from BARDA to supply CYFENDUS anthrax vaccine for preparedness efforts.14d ago